Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 14/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17405112 | 0.89 | LMNA (0.50) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL17405120 | 0.88 | MAPT (0.53) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL16903295 | 0.88 | MAPT (0.53) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL16903219 | 0.86 | LMNA (0.59) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL17405119 | 0.86 | MAPT (0.48) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL16903292 | 0.86 | MAPT (0.48) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL17405117 | 0.86 | MAPT (0.48) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL16903284 | 0.86 | MAPT (0.48) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL28449581 | 0.83 | MAPT (0.58) | LMNATSHRMAPTHTTSMN1; SMN2 | |
| SCHEMBL16903644 | 0.82 | MAPT (0.56) | LMNATSHRMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9339510-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339510-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160000812-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000812-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000812-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | LMNA 2166/4885TSHR 3422/4885MAPT 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.